Filiano AJ, Xu Y, Tustison NJ, Marsh RL, Baker W, Smirnov I, et al
Tirzepatide at its starting dose of 2.5mg may take longer to produce noticeable appetite effects because this dose is primarily intended for tolerability rather than efficacy
The shot is typically administered in the upper arm, and are considered safe for those with a diagnosed deficiency
Pilot clinical studies and case reports describe nausea in 65% of subjects at doses above 0,5 mg (resolution 2-4 h post-injection), flushing in 55%, transient increases in blood pressure and tachycardia in 40-60% of subjects, with peak acute effects occurring 90-120 minutes post-dose
Ecotoxicol Environ Saf 212:112012